MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 01-31-2026
Autolus Therapeutics plc Operating Cash Flow 2011-2026 | AUTL
Annual Operating Cash Flow Autolus Therapeutics plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -206 M | -146 M | -112 M | -118 M | -118 M | -101 M | -19.8 M | -16.4 M | -9.85 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -9.85 M | -206 M | -94.1 M |
Quarterly Operating Cash Flow Autolus Therapeutics plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -75.6 M | - | - | -40.5 M | - | - | -42.4 M | - | - | - | - | - | - | - | -37.3 M | - | - | - | -24 M | - | - | - | -26.5 M | -19.8 M | - | - | - | -8.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -8.8 M | -75.6 M | -34.4 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-95.2 M | $ 18.46 | -0.22 % | $ 2.72 B | USA |
 |
Amgen
AMGN
|
11.5 B | $ 344.63 | 0.8 % | $ 185 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
180 M | $ 70.06 | 1.05 % | $ 9.37 B | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Biogen
BIIB
|
2.88 B | $ 179.46 | -0.24 % | $ 26.1 B | USA |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.7 | 3.85 % | $ 17 M | USA |
 |
Adagene
ADAG
|
-29.7 M | $ 2.6 | -5.45 % | $ 146 M | China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
181 M | $ 9.78 | 0.93 % | $ 1.57 B | Britain |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.14 | -0.95 % | $ 7.55 B |  Australia |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 4.32 | 7.67 % | $ 9.4 B |  Israel |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Compugen Ltd.
CGEN
|
49.6 M | $ 1.83 | -0.3 % | $ 164 M | Israel |
 |
Aeglea BioTherapeutics
AGLE
|
-157 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-23.4 M | $ 1.41 | - | $ 264 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Celldex Therapeutics
CLDX
|
-158 M | $ 24.98 | 1.54 % | $ 1.61 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 226.97 | 0.38 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Cellectis S.A.
CLLS
|
-105 M | $ 3.86 | 1.72 % | $ 116 M | France |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 109.35 | -3.87 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
-97.2 M | - | - | $ 269 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
Corcept Therapeutics Incorporated
CORT
|
198 M | $ 42.1 | 5.59 % | $ 4.35 B | USA |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
240 M | $ 24.77 | 1.93 % | $ 2.93 B | USA |
 |
Cardiff Oncology
CRDF
|
-37.7 M | $ 1.7 | -3.14 % | $ 81 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
295 M | $ 13.96 | 2.01 % | $ 4.31 B | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-52 M | $ 6.58 | - | $ 1.36 B | USA |